Lucina Biosciences

Executive Summary

Lucina Biosciences is a privately held biotechnology company founded in 2021 and headquartered in San Diego, California, with operational facilities in Aurora and Fort Collins, Colorado. The company specializes in the research, development, and processing of placental tissue allografts, targeting applications in regenerative medicine. Lucina emphasizes compliance with FDA regulations, current Good Tissue Practices (cGTP), and current Good Manufacturing Practices (cGMP), positioning itself as a quality-focused provider of biologic solutions. While still in its early stages, the company aims to address unmet needs in wound healing, orthopedic, and surgical applications through its allograft offerings. Despite its strong regulatory focus, Lucina Biosciences is at an early commercial stage with limited publicly available clinical data or revenue metrics. The regenerative medicine market is competitive, with many players offering similar placental-derived products. Lucina's success will hinge on differentiation, clinical evidence generation, and securing partnerships for distribution. The company's private status and sparse public information contribute to an uncertain outlook. However, its adherence to stringent manufacturing standards and the growing demand for advanced biologics provide a foundation for potential growth.

Upcoming Catalysts (preview)

• TBDFDA 510(k) Clearance or HCT/P Registration for Novel Allograft Product30% success
• TBDStrategic Partnership with Major Regenerative Medicine Distributor20% success
• TBDExpansion of cGMP Processing Facility or New Capabilities40% success